Analyst Research and Recommendations: Applied DNA Sciences, Inc. (APDN), Sangamo Therapeutics, Inc. (SGMO)

Applied DNA Sciences, Inc. (NASDAQ:APDN) tinted loss of -8.55% (-0.04 points) to US$0.54. The volume of 0.59 Million shares climbed down over an trading activity of 658.35 Million shares. EPS ratio determined by looking at last 12 month figures is -0.4. Over the same time span, the stock marked US$1.84 as its best level and the lowest price reached was US$0.3. The corporation has a market cap of US$23.66 Million.

Applied DNA Sciences, Inc. (NASDAQ:APDN)’s earnings per share has been growing at a 23.4 percent rate over the past 5 year when average revenue increase was noted as 13.9 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was -485.3 percent. The company’s institutional ownership is monitored at 6.1 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 69.1 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 3. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is worth US$983.6 Million and has recently fallen -1.68% to US$8.8. The latest exchange of 1.86 Million shares is below its average trading activity of 2.14 Million shares. The day began at US$9 but the price moved to US$8.83 at one point during the trading and finally capitulating to a session high of US$9.09. The stock tapped a 52-week high of US$27.5 while the mean 12-month price target for the shares is US$22.71.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.4, and a price to sales ratio of 13.91. For the past 5 years, the company’s revenue has grown 11%, while the company’s earnings per share has grown -10.6%. With an institutional ownership near 66.6%, it carries an earnings per share ratio of -0.69.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.